Barclays PLC trimmed its position in shares of BiomX Inc. (NYSEMKT:PHGE – Free Report) by 90.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,000 shares of the company’s stock after selling 225,000 shares during the quarter. Barclays PLC owned 0.14% of BiomX worth $26,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, Ikarian Capital LLC purchased a new stake in BiomX in the 3rd quarter worth $911,000. Institutional investors and hedge funds own 40.57% of the company’s stock.
BiomX Stock Performance
Shares of PHGE stock opened at $0.76 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. The stock has a market cap of $13.86 million, a price-to-earnings ratio of -1.02 and a beta of 1.26. The business has a 50-day simple moving average of $0.66 and a two-hundred day simple moving average of $1.34.
About BiomX
BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.
Further Reading
- Five stocks we like better than BiomX
- What Are Growth Stocks and Investing in Them
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What is MarketRank™? How to Use it
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
